Company news
Aligos Therapeutics, Inc. news in 2022
Aligos Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
December 13, 2022
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
November 3, 2022
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
November 1, 2022
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
October 18, 2022
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
October 17, 2022
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
October 13, 2022
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
August 3, 2022
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
July 26, 2022
Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184
July 24, 2022
Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European...
June 21, 2022
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
May 3, 2022
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
April 26, 2022
Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development
April 3, 2022
Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio
March 21, 2022
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
March 9, 2022
Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022
March 1, 2022
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)
January 25, 2022
Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH
January 10, 2022
Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133
January 5, 2022
Decks in 2022
- Investor Presentation (September 2022)
Investor deck · 42 slides · September 2022